Abstract
The concept of cardiac remodeling implies a complex mixture of myocardial ischemia, and increased wall stress that results in molecular, cellular and interstitial changes in the heart. Clinically, cardiac remodeling is manifested as a change in size, shape and function of the heart. Morphologically the key feature of remodeling is myocyte hypertrophy, myocyte loss from necrosis or apoptosis, as well as interstitial cell growth especially fibroblast proliferation leading to myocardial fibrosis. Cardiac remodeling is influenced by hemodynamic load, neurohumoral activation, and other factors that can further affect the remodeling process. Despite advances in the management of heart failure, morbidity and mortality still present major health care issues in these patients. Statins (HMG Coenzyme A reductase inhibitors) play a key role in the management of ischemic heart disease. Recent studies indicate that statins may modulate cardiac remodeling by affecting signals that cause fibroblast growth, and myocyte hypertrophy and loss. In this paper we review the mechanisms of cardiac remodeling and the mechanisms of potential beneficial effects of statins on cardiac remodeling.
Keywords: statins, cardiac remodeling, heart failure, cardiomyopathy, fibrosis, hypertrophy
Current Vascular Pharmacology
Title: Modulation of Cardiovascular Remodeling with Statins: Fact or Fiction?
Volume: 3 Issue: 1
Author(s): Rajasekhar Reddy, Georges Chahoud and J. L. Mehta
Affiliation:
Keywords: statins, cardiac remodeling, heart failure, cardiomyopathy, fibrosis, hypertrophy
Abstract: The concept of cardiac remodeling implies a complex mixture of myocardial ischemia, and increased wall stress that results in molecular, cellular and interstitial changes in the heart. Clinically, cardiac remodeling is manifested as a change in size, shape and function of the heart. Morphologically the key feature of remodeling is myocyte hypertrophy, myocyte loss from necrosis or apoptosis, as well as interstitial cell growth especially fibroblast proliferation leading to myocardial fibrosis. Cardiac remodeling is influenced by hemodynamic load, neurohumoral activation, and other factors that can further affect the remodeling process. Despite advances in the management of heart failure, morbidity and mortality still present major health care issues in these patients. Statins (HMG Coenzyme A reductase inhibitors) play a key role in the management of ischemic heart disease. Recent studies indicate that statins may modulate cardiac remodeling by affecting signals that cause fibroblast growth, and myocyte hypertrophy and loss. In this paper we review the mechanisms of cardiac remodeling and the mechanisms of potential beneficial effects of statins on cardiac remodeling.
Export Options
About this article
Cite this article as:
Reddy Rajasekhar, Chahoud Georges and Mehta L. J., Modulation of Cardiovascular Remodeling with Statins: Fact or Fiction?, Current Vascular Pharmacology 2005; 3 (1) . https://dx.doi.org/10.2174/1570161052773915
DOI https://dx.doi.org/10.2174/1570161052773915 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Roles of Cytochrome P450 in Ischemic Heart Disease
Current Drug Metabolism Metabolic Syndrome and Asthma
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Mechanisms of Endothelial Dysfunction: Clinical Significance and Preventive Non-Pharmacological Therapeutic Strategies
Current Pharmaceutical Design Recent Updates on Current and Upcoming Biomarkers for Cardiovascular Diseases
Current Pharmaceutical Design Heavy Metal Toxicity in Humans and its Preventive and Control Measures
Current Nutrition & Food Science Early Functional and Structural Microvascular Changes in Hypertension Related to Aging
Current Hypertension Reviews Update on the Treatments of Non-Alcoholic Fatty Liver Disease (NAFLD)
Cardiovascular & Hematological Disorders-Drug Targets New Perspectives of Infections in Cardiovascular Disease
Current Cardiology Reviews The Journey of the Non-Vascular Relief for Migraine: From ‘Triptans’ To ‘Ditans’
Current Clinical Pharmacology Antioxidants in Peripheral Arterial Disease
Current Drug Targets Nutraceuticals - An Emerging Era in the Treatment and Prevention of Cardiovascular Diseases
Current Pharmaceutical Biotechnology Novel Therapeutic Targets for Management of Type-2 Diabetes Mellitus
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) How Should Serum Uric Acid Concentrations be Interpreted in Patients with Hypertension?
Current Hypertension Reviews The Coronary Artery Risk Detection in Appalachian Communities (CARDIAC) Project: An 18 Year Review
Current Pediatric Reviews Inhibition of Major Drug Metabolizing CYPs by Common Herbal Medicines used by HIV/AIDS Patients in Africa– Implications for Herb- Drug Interactions
Drug Metabolism Letters Modeling Loss of Microvascular Wall Homeostasis during Glycocalyx Deterioration and Hypertension that Impacts Plasma Filtration and Solute Exchange
Current Neurovascular Research Relationships of Birthweight and Postnatal Growth with Metabolic Risk Factors in Junior School Children in Korea
Current Hypertension Reviews Oral Antiplatelet Therapy for Acute Coronary Syndromes: Aspirin, P2Y12 Inhibition and Thrombin Receptor Antagonists
Current Drug Targets Molecular Mechanisms of the Antiatherogenic Action of Adiponectin
Vascular Disease Prevention (Discontinued) Exercise-Induced Modulation of Endothelial Nitric Oxide Production
Current Pharmaceutical Biotechnology